Matrix Factor Determination with the Waters Regulated Bioanalysis System Solution

Similar documents
A High Sensitivity UPLC/MS/MS Method for the Analysis of Clopidogrel and Clopidogrel Carboxylic Acid Metabolite in Human K 2 EDTA Plasma

Rapid, Simple Impurity Characterization with the Xevo TQ Mass Spectrometer

Rapid Lipid Profiling of Serum by Reverse Phase UPLC-Tandem Quadrupole MS

O O H. Robert S. Plumb and Paul D. Rainville Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL. LC /MS conditions

Rapid Analysis of Water-Soluble Vitamins in Infant Formula by Standard-Addition

A Definitive Lipidomics Workflow for Human Plasma Utilizing Off-line Enrichment and Class Specific Separation of Phospholipids

UPLC/MS Monitoring of Water-Soluble Vitamin Bs in Cell Culture Media in Minutes

UPLC-MS/MS Analysis of Azole Antifungals in Serum for Clinical Research

Analysis of Testosterone, Androstenedione, and Dehydroepiandrosterone Sulfate in Serum for Clinical Research

Quantification of Budesonide Using UPLC and Xevo TQ-S

Reducing Sample Volume and Increasing Sensitivity for the Quantification of Human Insulin and 5 Analogs in Human Plasma Using ionkey/ms

Applying a Novel Glycan Tagging Reagent, RapiFluor-MS, and an Integrated UPLC-FLR/QTof MS System for Low Abundant N-Glycan Analysis

[ APPLICATION NOTE ] High Sensitivity Intact Monoclonal Antibody (mab) HRMS Quantification APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

Analysis of Rosuvastatin in Dried Blood Spot and Plasma Using ACQUITY UPLC with 2D Technology

Removal of Triton X-100 from Plasma Samples Using Mixed-Mode Solid Phase Extraction (SPE)

Providing a Universal, One-step Alternative to Liquid-Liquid Extraction in Bioanalysis

Meeting Challenging Requirements for the Quantitation of Regulated Growth Promoters Dexamethasone and Betamethasone in Liver and Milk

Development of a High Sensitivity SPE-LC-MS/MS Assay for the Quantification of Glucagon in Human Plasma Using the ionkey/ms System

USP Method Transfer of Ziprasidone HCl from HPLC to UPLC

Latest Innovations in LC/MS/MS from Waters for Metabolism and Bioanalytical Applications

Comparison of a UPLC Method across Multiple UHPLC Systems

Direct Analysis of Urinary Opioids and Metabolites by Mixed-Mode µelution SPE Combined with UPLC/MS/MS for Forensic Toxicology

[ APPLICATION NOTE ] UPLC-MS/MS Analysis of 45 Amino Acids Using the Kairos Amino Acid Kit for Biomedical Research INTRODUCTION APPLICATION BENEFITS

Method Development for the Analysis of Endogenous Steroids Using Convergence Chromatography with Mass Spectrometric Detection

Analysis of the Non-Ionic Surfactant Triton-X Using UltraPerformance Convergence Chromatography (UPC 2 ) with MS and UV Detection

Rapid Analysis of Bisphenols A, B, and E in Baby Food and Infant Formula Using ACQUITY UPLC with the Xevo TQD

Dr. Erin E. Chambers Waters Corporation. Presented by Dr. Diego Rodriguez Cabaleiro Waters Europe Waters Corporation 1

A Novel Solution for Vitamin K₁ and K₂ Analysis in Human Plasma by LC-MS/MS

[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

[ APPLICATION NOTE ] Oasis PRiME HLB Cartridge for Cleanup of Infant Formula Extracts Prior to UPLC-MS/MS Multiresidue Veterinary Drugs Analysis

Simultaneous Analysis of Intact Human Insulin and Five Analogs in Human Plasma Using μelution SPE and a CORTECS UPLC Column

Development of a Bioanalytical Method for Quantification of Amyloid Beta Peptides in Cerebrospinal Fluid

Challenges in Developing an Ultra-Sensitive Bioanalytical Method for Ethinylestradiol in Human Plasma

John Haselden 1, Gordon Dear 1, Jennifer H. Granger 2, and Robert S. Plumb 2. 1GlaxoSmithKline, Ware, UK; 2 Waters Corporation, Milford, MA, USA

Supplementary Information

INTRODUCTION CH 3 CH CH 3 3. C 37 H 48 N 6 O 5 S 2, molecular weight Figure 1. The Xevo QTof MS System.

A Metabolomics Approach to Profile Novel Chemical Markers for Identification and Authentification of Terminalia Species

The Application of UPLC/MS E for the Analysis of Bile Acids in Biological Fluids

Vitamin D Metabolite Analysis in Biological Samples Using Agilent Captiva EMR Lipid

UPLC/MS/MS Method for the Routine Quantification of Regulated and Non-Regulated Lipophilic Marine Biotoxins in Shellfish

A UPLC/MS Approach for the Diagnosis of Inborn Errors of Metabolism

Profiling Flavonoid Isomers in Highly Complex Citrus Juice Samples Using UPLC Ion Mobility Time-of-Flight Mass Spectrometry

Analysis of Food Sugars in Various Matrices Using UPLC with Refractive Index (RI) Detection

Analysis of N-Linked Glycans from Coagulation Factor IX, Recombinant and Plasma Derived, Using HILIC UPLC/FLR/QTof MS

[ APPLICATION NOTE ] A Generic Kit-Based Approach for LC-MS/MS Quantification of Urinary Albumin for Clinical Research APPLICATION BENEFITS

Rapid and Accurate LC-MS/MS Analysis of Nicotine and Related Compounds in Urine Using Raptor Biphenyl LC Columns and MS-Friendly Mobile Phases

[Application Note] TOXICOLOGY SCREENING BY UPLC/PDA IN COMBINATION WITH AN EXTENSIVE COMPOUND LIBRARY

Jody Dunstan, 1 Antonietta Gledhill, 1 Ailsa Hall, 2 Patrick Miller, 2 Christian Ramp 3. Waters Corporation, Manchester, UK 2

Analysis of anti-epileptic drugs in human serum using an Agilent Ultivo LC/TQ

A RAPID AND SENSITIVE UPLC/UV/MS METHOD FOR SIMVASTATIN AND LOVA S TAT IN IN SU P P O RT O F C L E A NING VA L I DAT IO N S T U DIES

Extraction of Aflatoxin M1 From Infant Formula Using ISOLUTE Myco SPE Columns prior to LC-MS/MS Analysis

Extraction of Multiple Mycotoxins From Nuts Using ISOLUTE Myco prior to LC-MS/MS Analysis

Extraction of Multiple Mycotoxins From Grain Using ISOLUTE Myco prior to LC-MS/MS Analysis

Extraction of 25-hydroxy Vitamin D from Serum Using ISOLUTE. PLD+ Prior to LC-MS/MS Analysis

GlycoWorks Sample Preparation Consumables

PosterREPRINT SIMULTANEOUS QUANTIFICATION OF PSYCHOTHERAPEUTIC DRUGS IN HUMAN PLASMA BY TANDEM MASS SPECTROMETRY

Fast Separation of Triacylglycerols in Oils using UltraPerformance Convergence Chromatography (UPC 2 )

[ APPLICATION NOTE ] Profiling Mono and Disaccharides in Milk and Infant Formula Using the ACQUITY Arc System and ACQUITY QDa Detector

Comprehensive Forensic Toxicology Screening in Serum using On-Line SPE LC-MS/MS

Jose Castro-Perez, Henry Shion, Kate Yu, John Shockcor, Emma Marsden-Edwards, Jeff Goshawk Waters Corporation, Milford, MA, U.S. and Manchester, UK

Probing for Packaging Migrants in a Pharmaceutical Impurities Assay Using UHPLC with UV and Mass Detection INTRODUCTION

The use of mobile-device data to better estimate dynamic population size for wastewater-based epidemiology

CHARACTERIZATION AND DETECTION OF OLIVE OIL ADULTERATIONS USING CHEMOMETRICS

A RAPID AND SENSITIVE ANALYSIS METHOD OF SUDAN RED I, II, III & IV IN TOMATO SAUCE USING ULTRA PERFORMANCE LC MS/MS

Profiling and Quantitation of Metabolomic Signatures for Breast Cancer Cell Progression

High resolution mass spectrometry for bioanalysis at Janssen. Current experiences and future perspectives

Simple Method (IS-MRM) to Monitor Lysophospholipids and Phospholipids During LC-MS Method Development via In-Source CID

High Throughput Extraction of Opiates from Urine and Analysis by GC/MS or LC/MS/MS)

Automated Lipid Identification Using UPLC/HDMS E in Combination with SimLipid

LC-MS/MS Method for the Determination of Tenofovir from Plasma

SEPARATION OF BRANCHED PFOS ISOMERS BY UPLC WITH MS/MS DETECTION

The setup and validation of an LC-MS/MS assay of Androstenedione & Testosterone a labs experience

[ APPLICATION NOTE ] The Separation of 8 -THC, 9 -THC, and Their Enantiomers by UPC 2 Using Trefoil Chiral Columns INTRODUCTION APPLICATION BENEFITS

A Robustness Study for the Agilent 6470 LC-MS/MS Mass Spectrometer

Detection of Cotinine and 3- hydroxycotine in Smokers Urine

The Comparison of High Resolution MS with Triple Quadrupole MS for the Analysis of Oligonucleotides

Dienes Derivatization MaxSpec Kit

Supplementary Information. Effects of Perfluorooctanoic Acid on Metabolic Profiles in Brain and Liver of Mouse by a

A NOVEL METHOD OF M/Z DRIFT CORRECTION FOR OA-TOF MASS SPECTROMETERS BASED ON CONSTRUCTION OF LIBRARIES OF MATRIX COMPONENTS.

AbsoluteIDQ p180 Kit. Targeted Metabolite Identifi cation and Quantifi cation

[ application note note ] ]

DETERMINATION OF CANNABINOIDS, THC AND THC-COOH, IN ORAL FLUID USING AN AGILENT 6490 TRIPLE QUADRUPOLE LC/MS

[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

ACQUITY UPLC WITH PDA DETECTION: DETERMINING THE SENSITIVITY LIMITS OF OXYBUTYNIN AND RELATED COMPOUNDS

Paul Silcock 1, Anna Karrman 2, and Bert van Bavel 2. Aim. Introduction. Sample preparation

SPE-LC-MS/MS Method for the Determination of Nicotine, Cotinine, and Trans-3-hydroxycotinine in Urine

Quantitation by High Resolution Mass Spectrometry: Case Study of TOF MS for the Quantitation of Allopurinol from Human Plasma

A Novel Platform of On-line Sample Pre-treatment and LC/MS/MS Analysis for Screening and Quantitation of Illicit Drugs in Urine

4.5 Minute Analysis of Benzodiazepines in Urine and Whole Blood Using LC/MS/MS and an Ultra Biphenyl Column

Lipid Class Separation Using UPC 2 /MS

Chemical Analysis Business Operations Waters Corporation Milford MA

Extraction of a Comprehensive Steroid Panel from Human Serum Using ISOLUTE. SLE+ Prior to LC/MS-MS Analysis

Uptake and Metabolism of Phthalate Esters by Edible Plants

Determination of Amantadine Residues in Chicken by LCMS-8040

Dry eye disease commonly known as atopic keratoconjunctivitis is an autoimmune disease of

Fast and easy separation of 23 drugs of abuse. including high, stable resolution of isobaric opioids from human urine by UHPLC-MS/MS

Robust extraction, separation, and quantitation of structural isomer steroids from human plasma by SPE-UHPLC-MS/MS

SYNAPT G2-S High Definition MS (HDMS) System

Analysis of Cholesterol-Lowering Drugs (Statins) Using Dried Matrix Spot Technology

Matrix-induced Signal Enhancement of Propamocarb in LC-MS/MS

Transcription:

Matrix Factor Determination with the Waters Regulated Bioanalysis System Solution Joanne Mather, Steve Cubbedge, Debadeep Bhattacharya, and Robert S. Plumb Waters Corporation, Milford, MA, U.S. A P P L I C AT ION B E N E F I T S Quantification of matrix factor is required for bioanalytical methods in support of pre-clinical and clinical studies, as the endogenous compounds in blood-derived products can cause ion suppression or enhancement leading to inaccurate results. The Waters Regulated Bioanalysis System Solution features workflow-driven software that controls both UPLC and MS instruments and provides advanced data management capabilities for regulated laboratories. The solution can be used to automatically determine the matrix factors of a bioanalytical assay. INTRODUCTION In the field of quantitative bioanalysis, LC/MS/MS is the analytical technique of choice due to its high sensitivity and selectivity. However, quantitative bioanalytical methods development by LC/MS/MS can be complicated by matrixderived interferences such as phospholipids. Matrix factor calculation has been the subject of much discussion in bioanalytical meetings, resulting in guidelines on its evaluations being recommended at the Crystal City conferences. As a part of the method validation process in bioanalysis, it is a requirement that ion suppression due to matrix effect be determined. However, the matrix factor calculation process can be time-consuming and tedious, requiring transfer of data to and from external software programs for advanced processing, a process which is often not 21 CFR Part 11 compliant. The Waters Regulated Bioanalysis System, featuring UNIFI informatics and data management, enables bioanalytical laboratories to acquire and process LC/MS/MS-derived information in a streamlined and compliant-ready workflow. In this application note, we describe the use of UNIFI software used with the ACQUITY UPLC I-Class/Xevo TQ-S systems for automated determination of the matrix factor for a bioanalytical assay of fluticasone propionate in plasma. Perform UPLC/MS/MS experiments for analyte, solvent, and blank matrix Waters solutions ACQUITY UPLC I-Class System Xevo TQ-S UNIFI Scientific Information System Process data in UNIFI from the sample list Solvent and matrix chromatograms are multiplied on a point-per-point basis with the analyte chromatogram key words Matrix factor, matrix calculator Matrix factor and any internal-standard - normalized matrix factor are displayed Figure 1. Matrix factor calculation workflow with UNIFI. 1

E X P E R IM E N TA L Sample preparation Plasma proteins were precipitated using acetonitrile Chromatography LC system: ACQUITY UPLC I-Class System LC column: ACQUITY UPLC BEH C 18 Column, 1.7 µm, 2.1 x 50 mm Column temp.: 45 C Sample temp.: 4 C Injection vol: 5 µl Flow rate: 600 µl/min Mobile phase A: 0.1% ammonium hydroxide in water Mobile phase B: Methanol Gradient 1: 5 to 95% B in 1 min Gradient 2: 5 to 95% B in 2 min RESULTS AND DISCUSSION The matrix factor calculation performed using the UNIFI Scientific Information System follows the workflow detailed in Figure 1. Following this protocol, the matrix factor is calculated by comparing LC/MS/MS signal response for the analyte in solvent, and blank matrix samples. Fluticasone propionate was analyzed in plasma following protein precipitation with acetonitrile. Two sets of experimental conditions were used, a short gradient of 1 min and a longer gradient of 2 min. The matrix factor was determined for different gradient profiles (1 and 2 min). The elution profile for fluticasone propionate was determined for each chromatographic method. Fluticasone propionate and its D3 internal standard were infused into the LC stream post-column for both the solvent blank and matrix blank. This process was performed under complete automation using the on-board fluidics of the Xevo TQ-S, eliminating the need for time-consuming re-plumbing of the system. UNIFI software was used to control the UPLC and MS instruments and also to process the data, including automatically calculating the matrix factor for all experiments. Figure 2 shows the sample list along with the well position, run time (min), injection volume (µl), flow rate, and the solvent reservoir for each sample in UNIFI software.. The left panel of the figure shows the particular position of the selected sample (plasma blank 5 that is infused with internal standard and analyte) in the Sample Manager. Mass spectrometry MS system: Capillary voltage: Cone voltage: Collision energy: Xevo TQ-S, ESI positive mode 1.0 kv 18 V 20 ev Data management UNIFI Scientific Information System 2

Figure 2. Selecting a method from the sample list in UNIFI software. The chromatograms of fluticasone propionate with a 1-min gradient are shown in Figures 3A and 3B. After the experiments are performed, any given sample from the sample list can be selected to display its chromatogram. Figure 3A displays a comparison of MRM of the fluticasone propionate with that of the D3 internal standard. As shown, fluticasone propionate has a retention time of 0.97 min. Fluticasone elutes in a region of the chromatogram where there appears to be severe matrix suppression. This suppression is reflected in the matrix factor, which is calculated at 0.35, illustrated in the bar chart within Figure 3A. Here, UNIFI software displays the summary plot of matrix factor for five injections of fluticasone propionate in the form of a histogram. Additionally, the summary plot can be represented in graphical mode, as shown in Figure 3B, showing the sample list displayed along with response, matrix factor, and percent suppression. The % CV for the matrix factor is also displayed in the summary. 3

3A 3B Figure 3. MRMs of fluticasone propionate, 1-min gradient. Figure A (left) shows a comparison of the MRM with the internal standard and the histograms comparing matrix factor of other samples containing fluticasone propionate. Figure B (right) shows a summary plot of matrix factors results obtained from a series of repeat injections of the sample. 4

4A 4B Figure 4. MRMs of fluticasone propionate, 2-min gradient, for comparative quantification of matrix factors for several injections of fluticasone propionate. Similar to the data shown in Figures 3A and 3B, the MRMs, matrix factors, and sample list are shown for the fluticasone propionate with a 2-min gradient (Figure 4). The retention time of the fluticasone propionate was determined to be 1.95 min for the 2-min gradient. 5

The matrix factor for the 2-min gradient for fluticasone propionate with its internal standard is shown in Figure 4A (left), which shows the MRM of fluticasone propionate with the matrix factors of several replicate determinations in the summary plot. The matrix factor of 0.90 obtained for fluticasone propionate differed significantly with the 2-min gradient, compared to that of the 1-min gradient, where it was 0.35. This implies that the analyte has moved a region of less interference when using the longer 2-min gradient. As illustrated, the Waters Regulated Bioanalysis System Solution featuring UNIFI software provides a simple, automated, and convenient approach to quantifying the matrix factor of an assay. Depending on chromatographic conditions, analytes can coelute with endogenous components in matrix and/or drug-derived metabolites. This coelution can lead to significant matrix effects and possible reduced assay robustness and accuracy. CONCLUSIONS The matrix calculator within the UNIFI Scientific Information System, part of the Waters Regulated Bioanalysis System Solution, offers an easy, secure approach to determining the matrix factor during the bioanalytical method development process, which helps identify methods that might be susceptible to matrix effects that could potentially affect long-term method robustness. UNIFI automatically determines the matrix factors of a given sample within a set of experiments and between different batches or lots. Data acquisition and calculations are performed within one software system, eliminating the need for the transfer of derived data to and from third-party software. This automated approach to the determination of the matrix factor eliminates the need to employ third-party software such as Microsoft Excel to determine the matrix factor. All processes, from system setup, to data acquisition, processing, and calculations are carried out within a single secure, compliant-ready, audit-traceable system solution. Waters, ACQUITY UPLC, UPLC, and Xevo are registered trademarks of Waters Corporation. UNIFI and The Science of What s Possible are trademarks of Waters Corporation. All other trademarks are the property of their respective owners. 2011 Waters Corporation. Produced in the U.S.A. June 2011 720004004en AG-PDF Waters Corporation 34 Maple Street Milford, MA 01757 U.S.A. T: 1 508 478 2000 F: 1 508 872 1990 www.waters.com